BPC-157 (Body Protection Compound-157) is a 15-amino-acid synthetic peptide derived from a protein in human gastric juice. It's one of the most researched healing peptides, with hundreds of animal studies on tissue repair, gut healing, tendon recovery, and neuroprotection. No human clinical trials exist. This is not medical advice.
Research-context information only. BPC-157 is a research peptide. Protocols, doses, and reactions reported below come from published research and self-reported community sources. This article reports what has been documented, not what should be done. Consult a licensed physician for personal medical decisions.
BPC-157 Dosing Table
Match your vial size below — reconstitution and dose math update automatically.
250 mcg
5 units
0.05 mL
Daily SubQMaintenance
500 mcg
10 units
0.1 mL
Daily SubQStandard
750 mcg
15 units
0.15 mL
Daily SubQ
1 mg
20 units
0.2 mL
Daily SubQLoading dose (rare)
Math assumes U-100 insulin syringes (1 mL = 100 units). Verify your syringe matches before injecting. Round half-units to the nearest visible mark.
30 units
0.3 mL
Running BPC-157? Share your protocol
Anonymous · about 20 seconds · see how yours compares
Quick Reference: Standard Protocol
Dose
500 mcg/day
Route
Subcutaneous injection (near injury site or abdomen)
Timing
AM and/or PM
Frequency
Every day
Cycle
8 weeks on, 8 weeks off
Vial size
10 mg
Reconstitution
2 mL bacteriostatic water → 5,000 mcg/mL
Syringe math
See conversion tables below
Storage
Refrigerate, use within 28 days
Community-reported protocols most commonly describe 500 mcg once daily for 8 weeks, then 8 weeks off. Some users split the dose AM/PM (250 mcg twice daily) for more consistent tissue levels, but the total daily dose stays at 500 mcg.
Cycling: 8 Weeks On, 8 Weeks Off
Community protocols describe 500 mcg daily for 8 weeks straight, then 8 weeks off before repeating. This aligns with the tissue repair timeline seen in animal studies -- rapid angiogenesis and growth factor activity in weeks 1-2, followed by remodeling through week 8 (Sikiric et al., 2006).
Community protocols describe no loading phase — dosing begins at the full 500 mcg on day one. BPC-157 is dosed every day (no weekly breaks) for the full 8-week cycle.
Routes of Administration
Subcutaneous injection (most common): For localized injuries, community protocols describe injecting within a few inches of the injury site. For systemic issues, the abdomen or love handle area is commonly used. BPC-157 distributes systemically regardless of injection site. Typical volume: 0.1-0.2 mL with a 29-31 gauge insulin syringe.
Oral: BPC-157 is uniquely stable in stomach acid. Oral dosing is viable especially for GI-specific issues -- ulcers, IBD, NSAID-induced gut damage (Sikiric, 1999). Bioavailability is lower than injection, so some protocols use higher oral doses.
Intramuscular: Used when targeting a specific muscle injury -- direct injection into the muscle belly. Less common than SC (Novinscak et al., 2008).
Reconstitution Quick Reference
2 mL
5,000 mcg/mL
Math: 10,000 mcg / 2 mL = 5,000 mcg/mL. For 500 mcg: 500 / 5,000 = 0.1 mL = 10 units. One vial lasts 20 days.
Community protocols describe gentle swirling — not shaking — to avoid degradation, with storage at 2–8°C and use within 28 days. For step-by-step instructions, dilution charts, and storage details, see the full BPC-157 Reconstitution Guide.
Dosing a BPC-157 / TB-500 Blend Vial
Many vendors sell pre-mixed blend vials (e.g., 10 mg BPC-157 + 10 mg TB-500). Both peptides are already combined -- every unit you draw contains equal parts of each.
Reconstitution (10 mg/10 mg blend with 2 mL BAC water -- 5,000 mcg/mL per peptide):
Conservative start
7.5 units
375 mcg
Mid-range
1,000 mcg
Standard protocol
For a 5 mg/5 mg blend with 2 mL BAC water (2,500 mcg/mL per peptide), double the units above for the same dose.